GlassScriptPhysician profile
Ellen I Edgar
NPI 1326343625
$8,790.55
in general payments reported to CMS, 2019-2025
37 companies · $664 in 2025
The $664 reported for 2025 was more than what a typical Clinical Neurophysiology provider received nationally (typical 2025 total: $435).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $988 · 2020: $825 · 2021: $1,492 · 2022: $1,284 · 2023: $1,520 · 2024: $2,018 · 2025: $664.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,201.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,201.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,814.29 | 2021-2025 | Qulipta, Ubrelvy, Botox |
| Pfizer INC. | $1,067.78 | 2023-2025 | |
| Allergan, INC. | $724.19 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $555.95 | 2020-2024 | |
| Amgen INC. | $456.35 | 2019-2025 | Uplizna |
| Biohaven Pharmaceutical Holding Company LTD. | $328.58 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $326.14 | 2020-2021 | |
| Amneal Pharmaceuticals LLC | $242.55 | 2019-2025 | Rytary, Crexont |
| Lundbeck LLC | $223.17 | 2020-2025 | Vyepti |
| Biogen, INC. | $194.46 | 2020-2025 | Leqembi, Vumerity |
| Lilly USA, LLC | $175.49 | 2020-2025 | Kisunla, Amyvid, Zepbound |
| Neurocrine Biosciences, INC. | $172.65 | 2024 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $153.59 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Boston Scientific Corporation | $133.33 | 2019 | |
| Alexion Pharmaceuticals, INC. | $130.12 | 2019-2024 | Ultomiris |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $125.00 | 2021 | |
| Akcea Therapeutics, INC. | $104.74 | 2019 | |
| Medtronic, INC. | $103.00 | 2022-2024 | Percept PC Brainsense |
| Ucb, INC. | $98.78 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $86.38 | 2019-2020 | |
| Abbott Laboratories | $80.02 | 2021 | |
| Eisai INC. | $70.27 | 2022-2025 | |
| Genzyme Corporation | $51.68 | 2020-2022 | |
| Medtronic USA, INC. | $49.77 | 2019 | |
| Merz Pharmaceuticals, LLC | $38.15 | 2024 | Xeomin |
| Avanir Pharmaceuticals, INC. | $34.44 | 2019 | |
| Bausch Health US, LLC | $32.73 | 2019 | |
| Promius Pharma LLC | $27.86 | 2019 | |
| Argenx US, INC. | $25.91 | 2022 | |
| Merz North America, INC. | $25.49 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $24.99 | 2024 | Rexulti |
| Sunovion Pharmaceuticals INC. | $23.11 | 2019 | |
| Mdd US Operations, LLC | $22.07 | 2019 | |
| Corium, LLC | $20.46 | 2023 | Adlarity |
| Harmony Biosciences LLC | $17.13 | 2021 | |
| Currax Pharmaceuticals LLC | $16.67 | 2021 | |
| Arbor Pharmaceuticals, INC. | $13.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ellen Edgar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.